Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|August 23, 2021
Integrated Inhaled Dose Development
Author(s)Catalent
With more than 30 years’ experience, Catalent offers end-to-end solutions for multiple inhalation dose forms.
With more than 30 years of experience in supporting the development of inhaled products, and full commercial-scale manufacturing capabilities for dry powder inhalers, metered dose inhalers and unit/bi-dose nasal sprays, Catalent offers complete, end-to-end solutions for today’s inhalation dose forms.
Catalent provides formulation feasibility, device selection and clinical supply services, through to commercial filling and packaging, as well as analytical testing, final product characterization and release testing to ensure accurate, consistent drug delivery.
URL:
Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873 USA
Tel. +1.888.765.8846
[email protected]
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
3
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
4
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
5